

(20496)

<b>Medical Benefit</b>		<b>Effective Date:</b> 01/01/14	<b>Next Review Date:</b> 09/20
<b>Preauthorization</b>	No	<b>Review Dates:</b> 09/13, 09/14, 09/15, 09/16, 09/17, 09/18, 09/19	

***This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.***

*The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.*

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>Who are taking statin drugs</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>Genetic testing for SLCO1B1 variants</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>Standard care without genetic testing for SLCO1B1 variants</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>Symptoms</li> <li>Quality of life</li> <li>Morbid events</li> <li>Treatment-related morbidity</li> </ul>

### DESCRIPTION

HMG-CoA reductase inhibitors, or statins, which are widely used to treat hypercholesterolemia, can cause muscle-related adverse events. Serious myopathy (i.e., myositis, rhabdomyolysis) can also occur and may be associated with variants in the SLCO1B1 gene. Commercially available tests for the presence of SLCO1B1 variants are marketed for use in predicting the risk of myopathy for patients taking statins.

### SUMMARY OF EVIDENCE

For individuals who are taking statin drugs who receive genetic testing for SLCO1B1 variants, the evidence includes a randomized controlled trial. Relevant outcomes are symptoms, quality of life, morbid events, and treatment-related morbidity. Direct evidence for clinical utility in this setting would come from studies demonstrating that using the SLCO1B1 genotype to inform statin therapy (statin dose or choice of specific drug) has positive outcomes in terms of lower rates of myopathy with adequate lipid control and tolerability of alternative treatments. One randomized controlled trial was identified that evaluated adherence to medication and lipid control in patients whose physicians were informed of the SLCO1B1 haplotype at the beginning or at the end of the study. No significant benefits were identified in adherence to medications or in pain with knowledge of the SLCO1B1 haplotype status. There was a decrease in low-density lipoprotein cholesterol at three months but not at eight months in the active intervention group. Interpretation of this trial is limited due to the lack of blinding of participants and short-term outcomes, which might have affected adherence to medications and patient responses on questionnaires. The evidence is insufficient to determine the effects of the technology on health outcomes.

## POLICY

Genetic testing for the presence of variants in the *SLCO1B1* gene to identify patients at risk of statin-induced myopathy is considered **not medically necessary**.

## POLICY GUIDELINES

### GENETICS NOMENCLATURE UPDATE

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical protocol review updates starting in 2017 (see Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the HUman Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"—to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

## GENETIC COUNSELING

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## BACKGROUND

### STATINS

HMG-CoA reductase inhibitors, or statin drugs, are the primary pharmacologic treatment for hypercholesterolemia worldwide. In the United States, an estimated 38 million people took statins in 2008.<sup>1</sup> The use of statins is

associated with an approximately 30% reduction in cardiovascular events across a wide variety of populations.<sup>2</sup>

### Statin-Induced Myopathy

Statins are associated with a known risk of muscle-related symptoms, which are the most common adverse events of statin drugs. Myopathy is a general term for muscle toxicity. Three categories of statin-induced myopathy were defined in 2002 by a joint committee of the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute<sup>3</sup>:

- Statin-induced myalgia, defined as any muscle symptoms that occur without an elevation of serum creatinine kinase;
- Statin-induced myositis, defined as muscle symptoms with an elevation of serum creatinine kinase; and
- Statin-induced rhabdomyolysis, defined as markedly severe muscle symptoms with an elevation of creatinine kinase greater than ten times normal with an elevation in serum creatinine.

Statin-induced myalgia is the most common manifestation of myopathy; it is characterized by muscle pain, cramps, fatigue, and/or weakness.<sup>4</sup> Myalgias without other clinical manifestations are not associated with clinically important adverse events and resolve when the statin is discontinued.

The incidence of myalgia varies widely. In clinical trials, it has been reported in 1.5% to 3.0% of patients; in most trials, the rate of myalgias in patients on statin therapy is not increased compared with placebo treatment.<sup>5</sup> In observational studies, higher rates of 10% to 15% have been reported.<sup>2</sup>

Myositis is much less common than myalgias, with an estimated rate of five per 100,000 patient-years, and an estimated per-person incidence of 0.01%.<sup>5</sup> In virtually all cases, myositis resolves with discontinuation of the statin.

Rhabdomyolysis is the most severe clinical manifestation of statin-induced myopathy and can be life-threatening. The National Lipid Association estimated that rhabdomyolysis occurs at a rate of 1.6 per 100,000 patient-years, and the U.S. Food and Drug Administration adverse events reporting system has estimated a rate of 0.7 per 100,000 patient-years.<sup>5</sup> A systematic review by Law et al (2006) combined results from 20 clinical trials and estimated the rate of rhabdomyolysis to be 1.6 cases per 100,000 patient-years.<sup>6</sup> Fatalities from statin-induced rhabdomyolysis can occur, but the mortality rate is not well-defined. The Food and Drug Administration has estimated that deaths from rhabdomyolysis occur at a rate of less than one death per million prescriptions.<sup>3</sup>

A number of clinical factors are associated with an increased risk of statin-induced myopathy. Statin dose is probably the strongest risk factor, with an estimated 6-fold increase for patients on high-dose statins<sup>7</sup> (age is also a strong risk factor). A study by Schech et al (2007) reported that patients older than 65 years of age required hospitalization for statin-induced myositis at a rate that was four times higher than for younger patients.<sup>8</sup> Some statins may be associated with a higher risk than others, and concomitant administration of certain drugs (e.g., gemfibrozil, amiodarone) has been associated with higher rates of statin myopathy in clinical trials.<sup>7</sup> Other factors that may be associated with myopathy include female sex and intense physical exercise.<sup>7</sup> The perceived risk of statin-induced myopathy may contribute to suboptimal statin use in patients with indications. It is estimated that less than 50% of patients in the United States who would benefit from statins are currently taking them, a substantial percentage of whom do not adhere to prescribed statin regimens.<sup>1</sup>

### Genetic Factors Associated With Statin-Induced Myopathy

A variety of genetic factors are associated with statin myopathy. The cytochrome p450 system in the liver is the main pathway by which statins are metabolized. Numerous genetic variants in cytochrome p450 proteins affect the pharmacokinetics of statin metabolism and serum statin levels.<sup>2</sup> Other genetic variants affect statin metabolism, efficacy, and susceptibility to adverse events; these genetic variants involve variations in the apolipopro-

teins such as apo E, variations in the cholesterol ester transfer proteins, or variations in the coenzyme Q pathway.<sup>1</sup>

Variations in the SLCO1B1 gene also affect statin metabolism and are among the most well studied genetic variants. These variants are the genetic markers for which there are commercially available tests. This gene codes for a transporter protein that is part of the solute carrier organic ion transporter system, which mediates the influx and metabolism of statins in the liver.<sup>2</sup> Single nucleotide variants in this gene are associated with variations in the risk of statin-induced myopathy. The T/T allele is the wild-type and associated with the lowest risk of myopathy. The C/C allele is associated with the highest risk of myopathy, and the T/C allele with an intermediate risk. The T allele has a prevalence of approximately 87%, and the C allele has a prevalence of approximately 13%.<sup>4</sup>

Other genes have been studied, including ABCB1, which encodes ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1/P-glycoprotein 1), ABCG2, which encodes ABC transporters subfamily G member 2 (ABCG2/breast cancer resistance protein), and the coenzyme Q2 (COQ2) homolog gene. Other studies have evaluated the association between variants in the GATM gene and statin-induced myopathy (the GATM gene encodes a glycine amidinotransferase that is the rate-limited enzyme in creatine biosynthesis). However, it should be noted that the association between variants has not been consistently replicated.<sup>9</sup>

#### Commercially Available SLCO1B Molecular Diagnostic Tests

Several commercial and academic labs offer genetic testing for statin-induced myopathy (SLCO1B1) variants, including Boston Heart Diagnostics and ARUP Laboratories. Other labs offer panel tests for drug metabolism that include the SLCO1B1 gene; for example, ApolloGen.

## REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The Boston Heart Statin Induced Myopathy (SLCO1B1) Genotype test and ARUP Laboratories Statin Sensitivity SLCO1B1 are available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the Food and Drug Administration has chosen not to require any regulatory review of this test.

---

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

## REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Vladutiu GD. Genetic predisposition to statin myopathy. *Curr Opin Rheumatol*. Nov 2008;20(6):648-655. PMID 18946323
2. Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. *Drug Saf*. Jan 1 2011;34(1):1-19. PMID 21142270
3. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. *Circulation*. Aug 20 2002;106(8):1024-1028. PMID 12186811
4. Search Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genome-wide study. *N Engl J Med*. Aug 21 2008;359(8):789-799. PMID 18650507
5. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol*. Apr 17 2006;97(8A):89C-94C. PMID 16581336
6. Law M, Rudnicka AR. Statin safety: a systematic review. *Am J Cardiol*. Apr 17 2006;97(8A):52C-60C. PMID 16581329
7. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. *Clin Pharmacol Ther*. Jul 2012;92(1):112-117. PMID 22617227
8. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. *Pharmacoepidemiol Drug Saf*. Mar 2007;16(3):352-358. PMID 16892458
9. Luzum JA, Kitzmiller JP, Isackson PJ, et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. *Cell Metab*. Apr 7 2015;21(4):622-627. PMID 25863251
10. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1\*5 genetic variant is associated with statin-induced side effects. *J Am Coll Cardiol*. Oct 20 2009;54(17):1609-1616. PMID 19833260
11. de Keyser CE, Peters BJ, Becker ML, et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. *Pharmacogenet Genomics*. Jan 2014;24(1):43-51. PMID 24263182
12. Danik JS, Chasman DI, MacFadyen JG, et al. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. *Am Heart J*. Jun 2013;165(6):1008-1014. PMID 23708174
13. Vassy JL, Chun S, Advani S, et al. Impact of SLCO1B1 pharmacogenetic testing on patient and healthcare outcomes: a systematic review. *Clin Pharmacol Ther*. Aug 23 2018. PMID 30137643
14. Voora D. Genetically Guided Statin Therapy (Report no. AFRL-SA-WP-TR-2017-0005). Wright-Patterson Air Force Base, OH: USAF School of Aerospace Medicine; 2017.
15. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. *Am J Med Genet C Semin Med Genet*. Mar 2014;166(1):45-55. PMID 24619595
16. Ramsey LB, Johnson SG, Caudle KE, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. *Clin Pharmacol Ther*. Oct 2014;96(4):423-428. PMID 24918167